Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Anika Therapeutics Inc. - Common Stock (NQ:ANIK)

10.06 -0.19 (-1.85%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 12, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	82,595
Open	10.15
Bid (Size)	9.550 (300)
Ask (Size)	12.50 (100)
Prev. Close	10.25
Today's Range	9.965 - 10.31
52wk Range	7.870 - 18.34
Shares Outstanding	14,828,456
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026

Today 16:01 EST

From Anika Therapeutics Inc.

Via GlobeNewswire

ANIKA INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Reminds Anika Therapeutics Investors to Contact the Firm Regarding the Ongoing Investigation on Behalf of Anika Stockholders

January 26, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

Performance

YTD	+7.6%	+7.6%
1 Month	+5.3%	+5.3%
3 Month	-0.4%	-0.4%
6 Month	+16.4%	+16.4%
1 Year	-42.9%	-42.9%

More News

ANIK INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Anika Therapeutics, Inc.

January 23, 2026

From Kirby McInerney LLP

Via Business Wire

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

Anika Therapeutics Announces Leadership Transition

January 08, 2026

From Anika Therapeutics Inc.

Via GlobeNewswire

ANIK Investigation: Investors Encouraged to Contact Kirby McInerney LLP

December 30, 2025

From Kirby McInerney LLP

Via Business Wire

Anika Therapeutics, Inc. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors ANIK

December 05, 2025

From Kirby McInerney LLP

Via GlobeNewswire

Anika (ANIK) Q3 2025 Earnings Call Transcript ↗

November 05, 2025

Via The Motley Fool

Anika Therapeutics Inc (NASDAQ:ANIK) Reports Q3 2025 Earnings Beat and Positive Regulatory Milestone ↗

November 05, 2025

Via Chartmill

Anika Therapeutics Reports Filing of Final PMA Module for Hyalofast® Cartilage Repair Scaffold and Data from U.S. Pivotal FastTRACK Phase III Study

November 05, 2025

From Anika Therapeutics Inc.

Via GlobeNewswire

Anika to Issue Third Quarter 2025 Financial Results on Wednesday, November 5, 2025

October 23, 2025

From Anika Therapeutics Inc.

Via GlobeNewswire

ANIKA INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Reminds Anika Therapeutics Investors to Contact the Firm Regarding the Ongoing Investigation on Behalf of Anika Stockholders

October 09, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

ANIKA (ANIK) ALERT: Bragar Eagel & Squire, P.C. is Investigating Anika Therapeutics, Inc. on Behalf of Anika Stockholders and Encourages Investors to Contact the Firm

September 25, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Anika Therapeutics, Inc. – ANIK

September 14, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK

September 10, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK

September 06, 2025

From Pomerantz LLP

Via GlobeNewswire

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 05, 2025

From Anika Therapeutics Inc.

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK

September 02, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK

August 29, 2025

From Pomerantz LLP

Via GlobeNewswire

ANIKA ALERT: Bragar Eagel & Squire, P.C. is Investigating Anika Therapeutics, Inc. on Behalf of Anika Stockholders and Encourages Investors to Contact the Firm

August 26, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK

August 25, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK

August 21, 2025

From Pomerantz LLP

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Is Investigating Nutex, Anika, Fluor, and Inspire Medical and Encourages Investors to Contact the Firm

August 20, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK

August 17, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK

August 13, 2025

From Pomerantz LLP

Via GlobeNewswire

Frequently Asked Questions

Is Anika Therapeutics Inc. - Common Stock publicly traded?

Yes, Anika Therapeutics Inc. - Common Stock is publicly traded.

What exchange does Anika Therapeutics Inc. - Common Stock trade on?

Anika Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Anika Therapeutics Inc. - Common Stock?

The ticker symbol for Anika Therapeutics Inc. - Common Stock is ANIK on the Nasdaq Stock Market

What is the current price of Anika Therapeutics Inc. - Common Stock?

The current price of Anika Therapeutics Inc. - Common Stock is 10.06

When was Anika Therapeutics Inc. - Common Stock last traded?

The last trade of Anika Therapeutics Inc. - Common Stock was at 02/12/26 04:00 PM ET

What is the market capitalization of Anika Therapeutics Inc. - Common Stock?

The market capitalization of Anika Therapeutics Inc. - Common Stock is 149.17M

How many shares of Anika Therapeutics Inc. - Common Stock are outstanding?

Anika Therapeutics Inc. - Common Stock has 149M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.